{"id":664,"date":"2026-04-12T17:44:10","date_gmt":"2026-04-12T17:44:10","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=664"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"luciselade-seladelpar-10-mgx30-capsules","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/zh\/product\/luciselade-seladelpar-10-mgx30-capsules\/","title":{"rendered":"\u53f8\u62c9\u5fb7\u5e15"},"content":{"rendered":"<p style=\"line-height:20px\"><span style=\"font-size:16px;;color:#3f3f3f\"><strong>HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>These highlights do not include all the information needed to use LuciSelade safely and effectively. See full prescribing information for LuciSelade.<\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>INDICATIONS AND USAGE<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">LuciSelade is a peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Limitations of Use <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Use of LuciSelade is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE AND ADMINISTRATION <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">The recommended dosage of LuciSelade is 10 mg orally once daily. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Administer LuciSelade with or without food.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE FORMS AND STRENGTHS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Capsules: 10&nbsp;mg\u00d730&nbsp;capsules<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>CONTRAINDICATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">None<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>WARNINGS AND PRECAUTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Fractures: Consider the risk of fracture in patients treated with LuciSelade. Monitor bone health according to current standards of care. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Liver Test Abnormalities: Obtain baseline clinical and laboratory liver assessments prior to starting LuciSelade and monitor during treatment. Interrupt or discontinue LuciSelade if the liver tests worsen. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Biliary Obstruction: Avoid use in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LuciSelade and treat as clinically indicated. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>ADVERSE REACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Most common adverse reactions (reported in \u22655% and higher compared to placebo) are headache, abdominal pain, nausea, abdominal distension, and dizziness.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DRUG INTERACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;OAT3 Inhibitors: Avoid concomitant use. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Strong CYP2C9 Inhibitors: Avoid concomitant use. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Rifampin: Monitor biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Dual Moderate CYP2C9 and Moderate to Strong CYP3A4 Inhibitors: Monitor closely for adverse effects. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;CYP2C9 Poor Metabolizers using Moderate to Strong CYP3A4 Inhibitors: Monitor more frequently for adverse effects. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;BCRP Inhibitors: Monitor closely for adverse effects. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Bile Acid Sequestrants: Administer at least 4 hours before or 4 hours after taking a bile acid sequestrant, or at as great an interval as possible. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>USE IN SPECIFIC POPULATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Hepatic Impairment: Monitor patients with cirrhosis for evidence of decompensation. Consider discontinuation if patient progresses to moderate or severe hepatic impairment (Child-Pugh B or C).<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>Storage <\/strong><strong><\/strong><\/span><\/p>\n<p><span style=\"font-size:16px;color:#3f3f3f\">Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/p>\n<p style=\"text-align: left; margin-top: 5px; margin-bottom: 16px; line-height: 24px;\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciSelade is a peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.<\/p>","protected":false},"featured_media":1789,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[48],"product_tag":[],"class_list":["post-664","product","type-product","status-publish","has-post-thumbnail","product_cat-other-medicines","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product\/664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/comments?post=664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/media\/1789"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/media?parent=664"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_brand?post=664"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_cat?post=664"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/zh\/wp-json\/wp\/v2\/product_tag?post=664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}